

# ASX RELEASE

4 September 2025

---

## Appendix 3Y – Change of Director’s Interest Notice

In accordance with Listing Rule 3.19A.2, please see the attached Appendix 3Y – Change of Director's Interest Notice.

**END**

### Enquiries

Anita Chow  
Chief Financial Officer, Acusensus Limited  
+61 408 261 554  
Email: [investor-relations@acusensus.com](mailto:investor-relations@acusensus.com)

Simon Hinsley  
Investor and Media Relations  
+61 401 809 653  
Email: [simon@nwrcommunications.com.au](mailto:simon@nwrcommunications.com.au)

This announcement is authorised by the Company Secretary of Acusensus Limited.

### About Acusensus

Acusensus is a technology company that was founded in 2018 with a mission to design and develop artificial intelligence enabled road safety solutions. Collaborating with governments and commercial stakeholders to tackle distracted driving globally is Acusensus’ first priority.

Acusensus has pioneered intelligent solutions that provide anywhere, anytime digital evidence that can be used in conjunction with law enforcement to drive behavioural change and improve road safety. Acusensus technology is used to detect and provide prosecutable evidence of distracted driving (mobile phone use), seatbelt compliance, speeding, railway crossing compliance and the monitoring of vehicles of interest.

Acusensus listed on the Australian Securities Exchange in January 2023. Acusensus is headquartered in Melbourne, Australia, with offices also in Sydney, Brisbane, Perth, Auckland, Wellington and Christchurch (New Zealand), London (United Kingdom) and Las Vegas (United States).

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Acusensus Limited
<b>ABN</b> 17 625 231 941

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Alexander Jannink
<b>Date of last notice</b>	13 December 2024

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Alexander Jannink is a director, shareholder and beneficiary of Jannink & Associates Pty Ltd ACN 622 744 870 as trustee for Jannink Family Trust
<b>Date of change</b>	3 September 2025
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"><li>15,130,262 fully paid ordinary shares.</li><li>510,660 unquoted options:<ol style="list-style-type: none"><li>210,000 unquoted options exercisable at A\$0.552 and expire on 20 April 2027;</li><li>220,500 unquoted options exercisable at A\$0.552 and expire on 30 June 2027; and</li><li>80,160 unquoted options exercisable at A\$0.552 and expire on 26 September 2031.</li></ol></li><li>508,549 unquoted performance rights.</li></ol>
<b>Class</b>	Fully paid ordinary shares and unquoted performance rights

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number acquired</b>	200,804 fully paid ordinary shares
<b>Number disposed</b>	200,804 performance rights
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	N/A (see "Nature of change" below)
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>15,331,066 fully paid ordinary shares.</li> <li>510,660 unquoted options: <ol style="list-style-type: none"> <li>210,000 unquoted options exercisable at A\$0.552 and expire on 20 April 2027;</li> <li>220,500 unquoted options exercisable at A\$0.552 and expire on 30 June 2027; and</li> <li>80,160 unquoted options exercisable at A\$0.552 and expire on 26 September 2031.</li> </ol> </li> <li>307,745 unquoted performance rights.</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	As previously disclosed, Mr Jannink was granted performance rights under, and subject to, the Acusensus Equity Incentive Plan Rules as part of his remuneration for the 2024 and 2025 financial years following shareholder approval at the relevant Acusensus Annual General Meetings. Each performance right provides an entitlement to receive a fully paid share with the grant vesting equally over three years, subject to the satisfaction of certain performance measures. In respect of the relevant tranches of performance rights, 100% of the performance rights vested based on the relevant performance measures. All vested performance rights were subsequently exercised by Mr Jannink with ordinary shares issued as a result.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.